Safety Evaluation of KX01 Ointment 1% in Japanese Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 16, 2021

Primary Completion Date

November 22, 2021

Study Completion Date

January 12, 2022

Conditions
Healthy Volunteer
Interventions
DRUG

KX01 ointment 1%

A total of 4 application sites (2 cm x 2 cm each) will be marked on each subject's back, placing 2 sites for KX01 ointment 1% and 2 sites for Placebo ointment. One set (KX01 ointment 1% and Placebo ointment patches) will be designated for irradiation and the other set will remain non-irradiated under open conditions.

DRUG

Placebo ointment

A total of 4 application sites (2 cm x 2 cm each) will be marked on each subject's back, placing 2 sites for KX01 ointment 1% and 2 sites for Placebo ointment. One set (KX01 ointment 1% and Placebo ointment patches) will be designated for irradiation and the other set will remain non-irradiated under open conditions.

Trial Locations (1)

171-0014

Medical Corporation HOUEIKAI, Sekino Clinical Pharmacology Clinic, Toshima-ku

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

PharmaEssentia Japan K.K.

INDUSTRY

lead

PharmaEssentia

INDUSTRY

NCT05245578 - Safety Evaluation of KX01 Ointment 1% in Japanese Healthy Male Subjects | Biotech Hunter | Biotech Hunter